Cancer-data analysis and cell experiments found that MLKL depletion increased sensitivity to GPX4-inhibitor ferroptosis across cancer cells, with lower glutathione, altered NRF2/KEAP1/SLC7A11 signaling, and impaired CHMP5-mediated membrane repair. CHMP5 overexpression partly rescued cells, but evidence remains bioinformatic and cellular, not therapeutic in animals or humans.
Key findings
- MLKL expression correlated with glutathione genes and reduced GPX4-inhibitor sensitivity. MLKL depletion increased ferroptosis, lowered glutathione, and disrupted NRF2/KEAP1/SLC7A11; KEAP1 knockdown only partly rescued. Depletion reduced CHMP5 and membrane translocation, increased HMGB1 after GPX4 inhibition, and CHMP5 overexpression partly reduced ferroptosis.
Why this matters globally
The two-arm mechanism offers a sensitization target for ferroptosis, but MLKL has broad roles in immunity and cell death, so systemic targeting may have off-target consequences.
Thai researcher contribution
Chulalongkorn Allied Health Sciences and BIOTEC, NSTDA with the US National Cancer Institute integrated clinical bioinformatics, proteomics, and functional rescue.
Limitations to consider
Patient-data correlations are noncausal, and cultured cells plus GPX4 inhibitors may not represent tumor microenvironment. No animal, toxicity, or patient outcome is reported. MLKL depletion has many downstream effects, and partial CHMP5 rescue shows the mechanism is not exclusive.